JAC Advance Access originally published online on October 9, 2006
Journal of Antimicrobial Chemotherapy 2006 58(6):1208-1214; doi:10.1093/jac/dkl406
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Efficacy of daptomycin in the treatment of experimental endocarditis due to susceptible and multidrug-resistant enterococci
Department of Fundamental Microbiology, University of Lausanne CH-1015 Lausanne, Switzerland
Received 22 June 2006; returned 8 August 2006; revised 1 September 2006; accepted 12 September 2006
*Corresponding author. Tel: +41-21-6925613; Fax: +41-21-6925605; E-mail: Jose.Entenza{at}unil.ch
Objectives: Daptomycin was tested in vitro and in rats with experimental endocarditis against the ampicillin-susceptible and vancomycin-susceptible Enterococcus faecalis JH2-2, the vancomycin-resistant (VanA type) mutant of strain JH2-2 (strain JH2-2/pIP819), and the ampicillin-resistant and vancomycin-resistant (VanB type) Enterococcus faecium D366.
Methods: Rats with catheter-induced aortic vegetations were treated with doses simulating intravenously kinetics in humans of daptomycin (6 mg/kg every 24 h), amoxicillin (2 g every 6 h), vancomycin (1 g every 12 h) or teicoplanin (12 mg/kg every 12 h). Treatment was started 16 h post-inoculation and continued for 2 days.
Results: MICs of daptomycin were 1, 1 and 2 mg/L, respectively, for strains JH2-2, JH2-2/pIP819 and D366. In time–kill studies, daptomycin showed rapid (within 2 h) bactericidal activity against all strains. Daptomycin was highly bound to rat serum proteins (89%). In the presence of 50% rat serum, simulating free concentrations, daptomycin killing was maintained but delayed (6–24 h). In vivo, daptomycin treatment resulted in 10 of 12 (83%), 9 of 11 (82%) and 11 of 12 (91%) culture-negative vegetations in rats infected with strains JH2-2, JH2-2/pIP819 and D366, respectively (P < 0.001 compared to controls). Daptomycin efficacy was comparable to that of amoxicillin and vancomycin for susceptible isolates. Daptomycin, however, was significantly (P < 0.05) more effective than teicoplanin against the glycopeptide-susceptible strain JH2-2 and superior to all comparators against resistant isolates.
Conclusions: These results support the use of the newly proposed daptomycin dose of 6 mg/kg every 24 h for treatment of enterococcal infections in humans.
Keywords: cyclic lipopeptides , amoxicillin , glycopeptides , human kinetics , resistance
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. M. Entenza, A. Haldimann, M. Giddey, S. Lociuro, S. Hawser, and P. Moreillon Efficacy of Iclaprim against Wild-Type and Thymidine Kinase-Deficient Methicillin-Resistant Staphylococcus aureus Isolates in an In Vitro Fibrin Clot Model Antimicrob. Agents Chemother., September 1, 2009; 53(9): 3635 - 3641. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. E. Warren Daptomycin in endocarditis and bacteraemia: a British perspective J. Antimicrob. Chemother., November 1, 2008; 62(suppl_3): iii25 - iii33. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. I. Montero, F. Stock, and P. R. Murray Mechanisms of Resistance to Daptomycin in Enterococcus faecium Antimicrob. Agents Chemother., March 1, 2008; 52(3): 1167 - 1170. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. E. Falagas, K. P. Giannopoulou, F. Ntziora, and K. Z. Vardakas Daptomycin for endocarditis and/or bacteraemia: a systematic review of the experimental and clinical evidence J. Antimicrob. Chemother., July 1, 2007; 60(1): 7 - 19. [Abstract] [Full Text] [PDF]
|
|